1-5 of 5
Young-Kwang Yoon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib

Free
Ahrum Min, Seock-Ah Im, Young-Kwang Yoon, Sang-Hyun Song, Hyun-Jin Nam, Hyung-Seok Hur, Hwang-Phill Kim, Kyung-Hun Lee, Sae-Won Han, Do-Youn Oh, Tae-You Kim, Mark J. O'Connor, Woo-Ho Kim, Yung-Jue Bang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (6): 865–877.
https://doi.org/10.1158/1535-7163.MCT-12-0950
Published: 09 June 2013
View articletitled, RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib
Open the PDF for RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib in another window
Includes: Supplementary data
Journal Articles

Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer

Free
Hyun-Jin Nam, Seock-Ah Im, Do-Youn Oh, Paul Elvin, Hwang-Phill Kim, Young-Kwang Yoon, Ahrum Min, Sang-Hyun Song, Sae-Won Han, Tae-You Kim, Yung-Jue Bang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (1): 16–26.
https://doi.org/10.1158/1535-7163.MCT-12-0109
Published: 13 January 2013
View articletitled, Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer
Open the PDF for Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract A252: KRAS mutant lung cancer cells are differentially responsive to MEK inhibition due to AKT or STAT3 activation: Implication for combinatorial approach

Free
Young‐Kwang Yoon, Hwang‐Phill Kim, Sae‐Won Han, Seock‐Ah Im, Do Youn Oh, Yung‐Jue Bang, Tae‐You Kim
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A252.
https://doi.org/10.1158/1535-7163.TARG-09-A252
Published: 10 December 2009
View articletitled, Abstract A252: KRAS mutant lung cancer cells are differentially responsive to MEK inhibition due to AKT or STAT3 activation: Implication for combinatorial approach
Journal Articles

Abstract B260: Antitumor activity of HM781‐36B, an irreversible pan‐HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer cells

Free
Hyun‐Jin Nam, Hwang‐Phill Kim, Young‐Kwang Yoon, Hyung‐Seok Hur, Maeng‐Sup Kim, Gwan‐Sun Lee, Sae‐Won Han, Do‐Youn Oh, Seock‐Ah Im, Tae‐You Kim, Yung‐Jue Bang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B260.
https://doi.org/10.1158/1535-7163.TARG-09-B260
Published: 10 December 2009
View articletitled, Abstract B260: Antitumor activity of HM781‐36B, an irreversible pan‐HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer cells
Journal Articles

Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells

Free
Young-Kwang Yoon, Hwang-Phill Kim, Sae-Won Han, Hyung-Seok Hur, Do Youn Oh, Seock-Ah Im, Yung-Jue Bang, Tae-You Kim
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (9): 2526–2536.
https://doi.org/10.1158/1535-7163.MCT-09-0300
Published: 17 September 2009
View articletitled, Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells
Open the PDF for Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells in another window
Includes: Supplementary data